Online inquiry

IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10074MR)

This product GTTS-WQ10074MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10074MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4517MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ8079MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ7081MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ14268MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ14908MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ880MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ6162MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ6559MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA D2E7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW